首页> 外文期刊>Nucleic Acids Research >Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.
【24h】

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

机译:靶向Flt-1和KDR mRNA的抗血管生成核酶的生物活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR play important roles in physiological and pathological angiogenesis. Ribozymes that target the VEGF receptor mRNAs were developed and their biological activities in cell culture and an animal model were assessed. Ribozymes targeting Flt-1 or KDR mRNA sites reduced VEGF-induced proliferation of cultured human vascular endothelial cells and specifically lowered the level of Flt-1 or KDR mRNA present in the cells. Anti- Flt-1 and KDR ribozymes also exhibited anti-angiogenic activity in a rat corneal pocket assay of VEGF-induced angiogenesis. This report illustrates the anti-angiogenic potential of these ribozymes as well as their value in studying VEGF receptor function in normal and pathophysiologic states.
机译:血管内皮生长因子(VEGF)及其受体Flt-1和KDR在生理和病理性血管生成中起重要作用。开发了靶向VEGF受体mRNA的核酶,并评估了它们在细胞培养和动物模型中的生物学活性。靶向Flt-1或KDR mRNA位点的核酶可降低VEGF诱导的培养人血管内皮细胞的增殖,并特别降低细胞中Flt-1或KDR mRNA的水平。抗Flt-1和KDR核酶在VEGF诱导的血管新生的大鼠角膜囊化试验中也显示出抗血管生成活性。该报告说明了这些核酶的抗血管生成潜力及其在研究正常和病理生理状态下VEGF受体功能中的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号